Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan vs Dobutamine vs Milrinone in ADHF with Renal Impairment
NCT07186062Phase 4Completed
- Sponsor
- Ain Shams University
- Start
- Jun 2022
- Primary completion
- Jun 2024
- Countries
- 1
01
Overview
A Phase 4 trial of levosimendan, dobutamine, milrinone in heart failure (HF), cardiorenal syndrome (CRS), sponsored by Ain Shams University. Started Jun 2022; status: completed.
02
Drugs
levosimendandobutaminemilrinone
03
Conditions
heart failure (HF)cardiorenal syndrome (CRS)
Beyond the preview
Go deeper on NCT07186062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07186062.